Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N335
UPID:
GPD1L_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N335; A8K9U3; Q14702; Q9BRM5
Background:
Glycerol-3-phosphate dehydrogenase 1-like protein, encoded by the gene with accession number Q8N335, plays a crucial role in cardiac physiology. It regulates cardiac sodium current, influencing heart rhythm and function. Alterations in its activity can affect the balance of NAD(H), leading to changes in cardiac sodium current.
Therapeutic significance:
The protein is implicated in Brugada syndrome 2, a serious heart condition characterized by abnormal ECG patterns and risk of sudden death. Understanding its role could lead to novel interventions for this and potentially other cardiac disorders.